The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net earnings | 4,233 | 4,286 | 4,873 | 11,845 |
| Depreciation | 762 | 764 | 752 | 778 |
| Amortization of intangible assets | 7,377 | 7,622 | 7,946 | 7,689 |
| Deferred income taxes | -492 | -1,449 | -2,889 | -1,931 |
| Change in fair value of contingent consideration liabilities | 6,495 | 3,771 | 5,128 | 2,761 |
| Payments of contingent consideration liabilities | 2,865 | 1,995 | 870 | - |
| Stock-based compensation | 955 | 911 | 747 | 671 |
| Acquired ipr&d and milestones | 5,016 | 2,757 | 778 | 697 |
| Other charges related to collaborations | - | - | 0 | 0 |
| Gain on divestitures | - | 0 | 0 | 172 |
| Non-cash litigation reserve adjustments, net of cash payments | -933 | 508 | -443 | 2,243 |
| Impairment of intangible assets | 847 | 4,476 | 4,229 | 770 |
| Other, net | 3 | 63 | 225 | 150 |
| Accounts receivable | 1,490 | -207 | -66 | 1,455 |
| Inventories | 234 | 319 | 417 | 686 |
| Prepaid expenses and other assets | 827 | -361 | 188 | 264 |
| Accounts payable and other liabilities | 951 | 177 | 3,840 | 1,605 |
| Income tax assets and liabilities, net | -762 | -3,208 | -488 | 542 |
| Cash flows from operating activities | 19,030 | 18,806 | 22,839 | 24,943 |
| Acquisition of businesses, net of cash acquired | 204 | 17,493 | 0 | 255 |
| Other acquisitions and investments, net of cash acquired | 5,237 | 3,024 | 1,223 | 539 |
| Acquisitions of property and equipment | 1,214 | 974 | 777 | 695 |
| Purchases of investment securities | 35 | 73 | 77 | 1,438 |
| Sales and maturities of investment securities | 76 | 555 | 55 | 1,530 |
| Other, net | 29 | -189 | -13 | -774 |
| Cash flows from investing activities | -6,643 | -20,820 | -2,009 | -623 |
| Net change in commercial paper borrowings with original maturities of three months or less | 499 | - | - | - |
| Proceeds from short-term debt | 4,798 | 5,008 | - | - |
| Repayments of other short-term debt | 2,798 | 5,008 | - | - |
| Proceeds from issuance of long-term debt | 3,994 | 16,963 | - | 2,000 |
| Repayments of long-term debt and finance lease obligations | 6,797 | 9,613 | 4,149 | 14,433 |
| Debt issuance costs | 23 | 99 | 38 | 0 |
| Dividends paid | 11,657 | 11,025 | 10,539 | 10,043 |
| Purchases of treasury stock | 980 | 1,708 | 1,972 | 1,487 |
| Proceeds from the exercise of stock options | 172 | 214 | 180 | 262 |
| Payments of contingent consideration liabilities | 0 | 0 | 752 | 1,132 |
| Other, net | 68 | 57 | 48 | 30 |
| Cash flows from financing activities | -12,724 | -5,211 | -17,222 | -24,803 |
| Effect of exchange rate changes on cash and equivalents | 42 | -65 | 5 | -62 |
| Net change in cash and equivalents | -295 | -7,290 | 3,613 | -545 |
| Cash and equivalents, beginning of year | 5,524 | 12,814 | 9,201 | 9,746 |
| Cash and equivalents, end of year | 5,229 | 5,524 | 12,814 | 9,201 |
AbbVie Inc. (ABBV)
AbbVie Inc. (ABBV)